These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15777218)

  • 21. Prodrugs: a challenge for the drug development.
    Zawilska JB; Wojcieszak J; Olejniczak AB
    Pharmacol Rep; 2013; 65(1):1-14. PubMed ID: 23563019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-directed enzyme prodrug therapy.
    Connors TA
    Cancer Cells; 1990 Feb; 2(2):56-7. PubMed ID: 2397145
    [No Abstract]   [Full Text] [Related]  

  • 23. Recent advances in small molecule prodrugs for cancer therapy.
    Wang P; Jin X; Cai J; Chen J; Ji M
    Anticancer Agents Med Chem; 2014 Mar; 14(3):418-39. PubMed ID: 23869777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prodrug activation enzymes in cancer gene therapy.
    Aghi M; Hochberg F; Breakefield XO
    J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
    Leu YL; Chen CS; Wu YJ; Chern JW
    J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting: the ADEPT story so far.
    Bagshawe KD
    Curr Drug Targets; 2009 Feb; 10(2):152-7. PubMed ID: 19199911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
    Bagshawe KD; Sharma SK; Begent RH
    Expert Opin Biol Ther; 2004 Nov; 4(11):1777-89. PubMed ID: 15500406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
    Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in antibody-directed enzyme prodrug therapy.
    Sharma SK; Bagshawe KD; Begent RH
    Curr Opin Investig Drugs; 2005 Jun; 6(6):611-5. PubMed ID: 15997480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies on the development of small molecule anticancer drugs for targeted therapy.
    Lu YH; Gao XQ; Wu M; Zhang-Negrerie D; Gao Q
    Mini Rev Med Chem; 2011 Jun; 11(7):611-24. PubMed ID: 21699492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
    Sharma SK; Bagshawe KD
    Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of cytotoxic agents by targeted enzymes.
    Senter PD; Wallace PM; Svensson HP; Vrudhula VM; Kerr DE; Hellström I; Hellström KE
    Bioconjug Chem; 1993; 4(1):3-9. PubMed ID: 8431510
    [No Abstract]   [Full Text] [Related]  

  • 33. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy.
    Hayashi JY; Tamanoi F
    Enzymes; 2017; 42():153-172. PubMed ID: 29054269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia Responsive Drug Delivery Systems in Tumor Therapy.
    Alimoradi H; Matikonda SS; Gamble AB; Giles GI; Greish K
    Curr Pharm Des; 2016; 22(19):2808-20. PubMed ID: 26898739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developments with targeted enzymes in cancer therapy.
    Bagshawe KD; Sharma SK; Burke PJ; Melton RG; Knox RJ
    Curr Opin Immunol; 1999 Oct; 11(5):579-83. PubMed ID: 10508703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
    Chen KC; Schmuck K; Tietze LF; Roffler SR
    Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzymatically Cleavable siRNA Prodrugs: a New Paradigm for the Intracellular Delivery of RNA-Based Therapeutics.
    Ducho C
    ChemMedChem; 2015 Oct; 10(10):1625-7. PubMed ID: 26387983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
    Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
    Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
    Lehouritis P; Stanton M; McCarthy FO; Jeavons M; Tangney M
    J Control Release; 2016 Jan; 222():9-17. PubMed ID: 26655063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.